Background: In renal cell carcinoma (RCC), the discovery of biomarkers for clinical use is a
priority. This study aimed to identify and validate diagnostic and prognostic serum markers …

BACKGROUND: Conventional renal cell carcinoma (RCC) is the most common renal
cancer. As the metastatic conventional RCC is practically incurable, there is a need for …

Background Published studies showed divergent results of the prognostic value of serum
amyloid A protein (SAA) in patients with different cancers. Therefore, we conducted this meta …

Background/Aim: Serum amyloid A (SAA) has been identified as a potential biomarker for
renal cell carcinoma. We examined its diagnostic value in patients of different tumor stages …

The aim of the present study was to evaluate the clinical significance of the concentration of
serum amyloid A (SAA) in patients with renal cell carcinoma (RCC). SAA protein was …

BACKGROUND: We recently identified apolipoprotein A2 (ApoA2) and serum amyloid α
(SAA) as independent prognosticators in metastatic renal cell carcinoma (mRCC) patients …

Background: Lung cancer is known as the top cancer killer in most developed countries.
However, there is currently no promising diagnostic or prognostic biomarker for lung cancer …

Background In metastatic renal cell cancer (mRCC), the Memorial Sloan-Kettering Cancer
Center (MSKCC) risk model is widely used for clinical trial design and patient management …

Objective: The objective of our present study was to assess the role of serum amyloid A
(SAA) in stages and prognosis of renal cell carcinoma. Material and Methods: It was a …

BACKGROUND Evidence of systemic inflammation, ie, elevation of serum C–reactive
protein, interleukin‐6, and/or the erythrocyte sedimentation rate, is correlated to poorer …